Medication info
Rotacan Tablet 20/32 Milligrams

Rotacan Tablet 20/32 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletCandesartan Cilexetil›32mg / 1 tablet
Manufacturer / importer
Noksi Pharma Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets (10 tablets/PTP X 3)
Approval status
Active

MFDS item code 201702408 · Approved 2017.05.16 · Insurance code 643605420

Summary

Main use
Treatment of hypertension and heart failure, improvement of hyperlipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. Elderly patients: No adjustment of the initial dose is necessary. Patients with intravascular volume depletion: For patients at increased risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger. The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger.

Ingredients

Manufacturer
Noksi Pharma Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of hyperlipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk

  • Essential hypertension
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used for patients who need to take Candesartan Cilexetil and Rosuvastatin together. Candesartan Cilexetil is effective for patients with essential hypertension or those with heart failure and impaired left ventricular function when additional treatment with ACE inhibitors is needed or if there is poor tolerance. Rosuvastatin helps with hypercholesterolemia and familial hypercholesterolemia that cannot be controlled by diet and exercise, slows the progression of atherosclerosis, and reduces cardiovascular disease risk. It is particularly used in patients with high-sensitive C-reactive protein levels and other additional cardiovascular risk factors to lower the risk of stroke, myocardial infarction, and vascular revascularization. These two medications help improve cardiovascular health by controlling blood pressure and cholesterol levels.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. Elderly patients: No adjustment of the initial dose is necessary. Patients with intravascular volume depletion: For patients at increased risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or more, up to a maximum of 32 mg once daily, depending on the patient's tolerability. Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger. The safety and efficacy of this medicine have not been established in adolescents and children 18 years of age or younger.

Precautions

This medication can cause severe harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately if pregnancy is confirmed. Patients with allergies to this drug or its components, those with active liver disease, women who are pregnant or breastfeeding, patients with severe liver impairment, those with myopathy, hereditary angioedema patients, those with severe kidney failure, and patients on certain other medications should not take this medicine. Elderly patients, those with hyperkalemia, mild to moderate liver impairment, and patients with heart or kidney-related diseases should take this medication with caution, requiring regular blood tests and monitoring of physical condition during treatment. This medication can cause serious muscle-related side effects such as myalgia, myopathy, and rarely rhabdomyolysis, so if symptoms of muscle pain or weakness occur, immediate consultation with a doctor is required. Possible liver function abnormalities may arise; therefore, liver function tests should be performed periodically before and during treatment, and if liver enzyme levels rise significantly, treatment should be discontinued. This medication may interact with other drugs, so it is crucial to inform the doctor or pharmacist of any other medications being taken, especially if combined with potassium-sparing diuretics, certain antibiotics, antifungals, immunosuppressants, etc. Women who are pregnant or breastfeeding should not use this medication, and those planning pregnancy should use appropriate contraceptive methods. The safety and efficacy of this medication have not been established in children, so it is not recommended for pediatric use. In case of overdose, symptoms such as hypotension, dizziness, and tachycardia may occur, requiring immediate treatment. During treatment, dizziness or fatigue may occur due to blood pressure lowering, so caution is advised while driving or operating machinery. Lastly, this medication should be kept out of reach of children and is safest when stored in its original container.

Side effects

headache, nasopharyngitis, localized infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, elevated blood glucose, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, nausea, dizziness, positional vertigo, xanthelasma, periodontitis, chest discomfort, inflammation, foreign body sensation, musculoskeletal pain, neck pain, cataract, increased blood pressure, orthostatic hypotension, cerebral infarction, spondyloarthritis, musculoskeletal discomfort, pneumonia, femoral fracture, contusion, unstable angina, productive cough, idiopathic pulmonary fibrosis, worsening hypertension, unstable blood pressure, vertigo, positional vertigo, adrenal insufficiency, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, thirst, sleep disorder, decreased libido, amnesia, anorexia, increased appetite, tinnitus, taste disturbance, erectile dysfunction, vascular edema, diabetes, constipation, abdominal pain, pancreatitis, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive decline, amnesic syndrome, memory impairment, confusion, myasthenia gravis, oculobulbar myasthenia, hypotension, renal function impairment, increased creatinine, increased urea, increased potassium, decreased sodium, elevated ALT, increased CK, weakness, fever, sensory disturbance, low back pain, respiratory infection, anxiety, depression, somnolence, dyspnea, increased sweating, thrombocytopenia, intestinal vascular edema, nausea, diarrhea, liver dysfunction, jaundice, urticaria, vascular edema, myalgia, weakness, rhabdomyolysis, arthralgia, myalgia, low back pain, renal function impairment, acute renal failure, interstitial pneumonia, shock, syncope, loss of consciousness, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, thirst, sleep disorder, decreased libido, amnesia, anorexia, increased appetite, tinnitus, taste disturbance, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, with a storage temperature maintained between 1 to 30 degrees Celsius. It is important to avoid direct sunlight or high temperatures, and to keep it in a place out of reach of children.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets (10 tablets/PTP X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.